Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A proteinuria and uremia technology, applied in the field of medicine, can solve problems such as the inability to effectively control the development of CRF, and achieve the effect of improving the nutritional status of the body and improving the therapeutic effect
Pending Publication Date: 2016-05-25
程潜
View PDF5 Cites 6 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
At present, Western medicine mainly treats CRF patients in the uremia stage with dialysis and kidney transplantation, but there is no specific drug for early and mid-stage CRF, and most of them rely on passive symptomatic treatment, which cannot effectively control the development of CRF
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0030] Embodiment 1 A kind of medicine for treating uremia and urinary protein
[0031] The drug is marine algae glycoprotein;
[0032] The marine algae glycoprotein, by weight content, includes 1% sugar and 99% protein;
[0033] The molecular weight is 0.2kDa;
[0034] The sugar is a polysaccharide;
[0035] The marine algae are cyanobacteria;
[0036] The polysaccharides include: glucose, galactose, mannose, rhamnose;
[0037] The protein includes: arginine, lysine, serine, threonine;
Embodiment 2
[0038] Embodiment 2 A kind of medicine for treating uremia and urinary protein
[0039] The drug is marine algae glycoprotein;
[0040] Said marine algae glycoprotein, by weight content, comprises sugar 7%, protein 88%,
[0041] The molecular weight is 19kDa;
[0042] The sugar is a polysaccharide;
[0043] The marine algae is: green algae;
[0044] The polysaccharides include: glucose, galactose, mannose, rhamnose;
[0045] The protein includes: arginine, lysine, serine, threonine;
Embodiment 3
[0046] Embodiment 3 A kind of medicine for treating uremia and urinary protein
[0047] The drug is marine algae glycoprotein;
[0048] Said marine algae glycoprotein, by weight content, comprises sugar 22%, protein 72%,
[0049] The molecular weight is 5kDa;
[0050] The sugar is a polysaccharide;
[0051] The marine algae are: cyanobacteria;
[0052] The polysaccharides include: glucose, galactose, mannose, rhamnose;
[0053] The protein includes: arginine, lysine, serine, threonine;
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
molecular weight
aaaaa
aaaaa
molecular weight
aaaaa
aaaaa
molecular weight
aaaaa
aaaaa
Login to view more
Abstract
The invention provides medicine for treating uremia and urine protein. The medicine is a mixture of glycoprotein or polysaccharide and protein or polypeptide or protein. The medicine achieves a good treatment effect for uremia and urine protein, and after three treatment courses are completed, the total effective rate is 84-94%; the medicine lowers toxin of uremia and urine protein and remarkably lowers the content of SCr, the content of urine protein and the content of blood urea nitrogen, after three treatment courses are completed, the SCr content of a patient is 282.4-290. micromole / L, the urine protein content is 2.42-2.54 g / 24h, and the blood urea nitrogen content is 14.2-15.0 mmol / L. The medicine improves the nutrition condition of the organism, raises the content of plasma albumin (Alb) and the content of hemoglobin (Hb), improves the immunity, has the advantages of being safe, high in efficiency and free of side effect and has an obvious treatment effect for uremia and urine protein.
Description
technical field [0001] The invention relates to a medicine for treating uremia and urinary protein, belonging to the technical field of medicine. Background technique [0002] Chronic renal failure refers to a clinical syndrome composed of a series of symptoms and metabolic disorders caused by various kidney diseases leading to progressive and irreversible decline in renal function until the loss of function, referred to as chronic renal failure. The end stage of chronic renal failure is what is often called uremia. Uremia is not an independent disease, but a clinical syndrome shared by various advanced kidney diseases, which is a syndrome composed of a series of clinical manifestations when chronic renal failure enters the terminal stage. [0003] Kidney disease is a clinical common disease, frequently-occurring disease. In recent years, the incidence rate has gradually increased, which is extremely harmful to people's health. Various kidney diseases develop to eventuall...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more